cyrilzakka/clinical-trials huggingface dataset:
Clinical Study on the Effect of IVF-ET on Mother-to-child Transmission of Hepatitis B Virus

This study is intended to retrospectively collect HBV-infected pregnant women and non-HBV-infected pregnant women who have been born in IVF in the investigators' hospital, collect pregnant women's data during pregnancy, newborn birth data, and hepatitis B virus in July after birth of newborns born to HBV-infected pregnant women. Infection, explore the impact of HBV infection on IVF outcomes and whether IVF operations increase the risk of mother-to-child transmission of HBV.

This study is a retrospective study that only retrospectively collects a variety of patient data and does not perform any treatment or examination on the patient. The research design is as follows: 1. All patients with HBV-infected pregnant women and non-HBV-infected pregnant women who had undergone IVF operation were retrospectively collected from the investigators' hospital HIS system. 2.Collecting pregnant women's data from the HIS system (including age, maternal history, liver function during pregnancy, HBV DNA in early pregnancy and before delivery, complication and complications during pregnancy, antiviral use before and during pregnancy, father HBV infection Status), neonatal birth data (including body length, weight, Apgar score, feeding status, hepatitis B vaccination, hepatitis B immunoglobulin use, HBsAg at birth and 7 months after birth, HBV DNA). 3. Statistical analysis: (1) Compare the body length, body weight, Apgar score of newborns born to pregnant women with HBV infection and non-HBV infection, and understand the effect of HBV infection on IVF outcomes. (2) Newborns born to HBV-infected pregnant women were divided into HBV DNA-negative group, low-viral group, and high-viral group according to HBV DNA status. The HBV infection status of these newborns was counted in July, and the different viral loads were tested. The impact on mother-to-child transmission of HBV. (3) When discussing whether IVF operation increases the rate of mother-to-child transmission of HBV, it is more scientific and persuasive to use HBV-infected pregnant women who have not been operated with IVF, but the incidence of twins in IVF is significantly higher than that of natural pregnancy. Further lead to premature birth, postpartum hemorrhage, cesarean section rate, etc., the weight and length of newborns are also affected, so it is difficult to match the appropriate population, so this study decided to HBV infection rate of different HBV DNA load IVF Compared with the literature, the corresponding viral load of HBV infection was compared with the rate of mother-to-child transmission of IVF pregnant women.

Eligibility Criteria:
Inclusion Criteria:

* pregnant women who have been IVF-operated
* HBV-infected pregnant women need to be positive for HBsAg for more than half a year.

Exclusion Criteria:

* Combined with pregnancy-induced hypertension, premature rupture of membranes, prenatal bleeding and other diseases;
* history of amniocentesis during pregnancy;
* combined with other viral infections: such as HCV, HIV, CMV.
SaRS-Cov-2 Antibodies Following Exposure to Coronavirus Disease 2019 (COVID-19) and/or Vaccination in Nursing Homes

Presence of SaRS-Cov-2 antibodies following exposure to Coronavirus Disease 2019 (COVID-19) and/or vaccination is a major indicator of immunization. Few data exit about serology response in nursing homes (NHs), i.e. in the most vulnerable population for developing severe forms of the disease.

Residents and health professionals in 9 nursing homes (NHs) with SaRS-Cov-2 antibodies detection after exposure (either COVID-19 or vaccine) All biological tests were performed in the frame of the standard care of residents and health professionals and all participants did not express opposition for using anonymously their data for the purpose of this academic analysis. In addition all Directors and Physicians of these NHs accepted to participate in this study


Eligibility Criteria:
Inclusion Criteria:

For Residents:

* Living in one of the 9 Nursing Homes that participate in this study
* Having a SARS-COV-2 post vaccination serology.
* Having no objection for using the results of the serology for the purpose of this analysis

For Health Professionals:

* Working in one of the 9 Nursing Homes that participate in this study,
* Having a SARS-COV-2 post vaccination serology.
* Having no objection for using the results of the serology for the purpose of this analysis

Exclusion Criteria:

* None
LINQ for impEdance meAsuremeNt While Off From HF Medication Study

The purpose of this non-randomized, cross-over, unblinded, single-center feasibility study is to assess the sensitivity of the LINQ ICM to measure derived-subcutaneous impedance in patients with heart failure during periods when diuretics and/or HF-medication consumption is increased or suspended for 48 hours (up to 72 hours at physician discretion) and to collect safety information related to HF status and to medication consumption changes.

Up to 30 subjects with a clinical diagnosis of Heart Failure will be enrolled in the study. It is expected that the subjects will be enrolled over a period of approximately 6 months.

3 follow up visits are planned at 2, 4 and 6 months (+/- one week) following the LINQ ICM implant.

The total expected duration of the study is of about 1 year. According to the enrolment chronological order, each subject will be allocated to Diuretic Suspension group (DS), Diuretic Increase (DI) or Diuretic+MRA medication Suspension (DMS), which will define the medication regimen before the follow-up visit.

Primary objective of the study is detecting the variation of impedance magnitude and the time of occurrence after medication regimen changes will be evaluated at each follow-up.

Eligibility Criteria:
Inclusion Criteria:

* Clinical Diagnosis of Heart Failure
* Plasma NT-proBNP (\>250ng/L in SR and \>1,000ng/L in AF)
* LVEF \<50% measured in the year before enrolment
* Treated routinely with a daily dose of loop diuretic
* Receiving other guideline-indicated therapy for heart failure
* Willing to sign the informed consent form.
* Greater than 18 years of age.

Exclusion Criteria:

* Pregnant patients (all females of child-bearing potential must have a negative pregnancy test before LINQ ICM implant)
* eGFR \<30 ml/minute.
* Any concomitant condition which in the opinion of the investigator would not allow a safe participation in the study.
* Patients with implanted pacemakers or defibrillators
* Severe aortic or mitral valve disease
* Breathlessness at rest or on minor exertion.
* Chest pain at rest or on mild or moderate exertion.
* Patients deemed too unstable to miss 48 hours of heart failure treatment
* Enrolled in another study that could confound the results of this study, without documented pre-approval from Medtronic study manager
Evaluation of LB in THA

This study aims to compare the effectiveness of liposomal bupivacaine (LB) versus standard of practice local injection containing plain bupivacaine.

Investigation of liposomal bupivacaine to determine if this drug is a valid alternative to standard of care local anesthesia based on evaluation in total hip arthroplasty This is a retrospective cohort study of consecutive patients undergoing THA at 3 hospitals within a U.S. healthcare system from January 2013 to July 2016. The control group received the standard of care undergoing THA (plain bupivacaine or ropivacaine), while the LB group received a mixture containing this drug as the alternative to the standard care. The outcome variables include hospital length of stay, readmissions, total hospital costs, patient pain scores, discharge disposition, morphine equivalent opioid consumption, and postoperative patient ambulation. Generalized linear models were employed to examine aforementioned outcomes controlling for age, gender, race, BMI, alcohol use, tobacco use, and surgeons..

Eligibility Criteria:
Inclusion Criteria:

* Males or females over the age of 18
* have undergone a THA surgery during the period of interest January 2013 to July 2016).

Exclusion Criteria:

* excluded from the study based on the following criteria:

  1. Concurrent, painful, physical condition or concurrent surgery that may require analgesic treatment in the postoperative period for pain that is not strictly related to the surgical treatment;
  2. Uncontrolled anxiety, schizophrenia, or other psychiatric disorder; and
  3. Significant renal or hepatic insufficiency.
Clinical Significance of Supranormal Differential Renal Function in the Recovery of Hydronephrosis

The purpose of this study is to assess the clinical significance of supranormal differential renal function (DRF) in the recovery of unilateral hydronephrosis (HN) after surgery, pediatric patients who underwent pyeloplasty for ureteropelvic junction obstruction (UPJO) who showed supranormal DRF (\> 55%) in the DTPA renography will be analyzed.

To assess the clinical significance of supranormal differential renal function (DRF) in the recovery of unilateral hydronephrosis (HN) after surgery, pediatric patients who underwent pyeloplasty for ureteropelvic junction obstruction (UPJO) who showed supranormal DRF (\> 55%) in the DTPA renography will be analyzed. Clinical parameters including age at the first visit, age at operation, gender, laterality, and follow-up period will be evaluated. To evaluate predictors of recovery from supranormal renal function according to the level of DRF, univariate and multivariate logistic regression analyses will be performed. Patients would be subcategorized into two groups; group A (DRF ≤60%) and group B (DRF \>60%) in consideration of the mean value of preoperative DRF and each parameter of group A was compared to that of group B using independent sample's t test and chi square test. Kaplan-Meier analysis and log-rank test will be used to determine the difference of recovery time of obstructed hydronephrosis in each parameter.

Eligibility Criteria:
Inclusion Criteria:

* ureteropelvic junction obstruction
* hydronephrosis
* differential renal function more than 55% in DTPA
* follow-up period more than 1 year

Exclusion Criteria:

* urological anomalies, such as vesicoureteral reflux, ureterocele, cystic kidney disease, posterior urethral valves, duplex anomalies, neurogenic bladder, and solitary kidney or patients who underwent any previous urological surgery
Oropharyngeal Aspiration to Reduce Ventilator-Related Pneumonia

Ventilator-associated pneumonia (VAP) is one of the healthcare-related infections that is common in critically ill patients, prolongs hospital stay, significantly increases mortality and additional health care costs.

Microaspiration of oropharyngeal secretions the primary pathway in the formation of VAP has led researchers to focus on the detection of applications to prevent microbial colonization. Continuous or intermittent oropharyngeal aspiration, open system aspiration versus closed system aspiration, extensive oral care, oropharyngeal aspiration prior to patient positioning are some of these applications.

When the patient is turned to position, the outbreak accumulated in the oral cavity is more likely to move to the lower respiratory tract. In this study, it is assumed that aspiration of oropharyngeal secretions prior to each position change will reduce the accumulation of oral secretion in the endotracheal tube cuff and reduce aspiration of contaminated secretion and reduce the risk of developing VIP. This randomized controlled experimental study was planned to confirm the validity of this assumption.

This study was a randomized controlled experimental study designed to investigate the effect of oropharyngeal aspiration on decreasing the incidence of ventilator-associated pneumonia in patients receiving mechanical ventilation. The research was conducted between July 2015 and April 2019 in anesthesiology and reanimation intensive care unit. The study was carried out with 20 patients who underwent oropharyngeal aspiration as needed and 20 patients with oropharyngeal aspiration prior to each change of position.


Eligibility Criteria:
Inclusion Criteria:

* Over 18 years of age,
* Supported mechanical ventilation by endotracheal tube,
* ≥ 24 hours remaining connected to mechanical ventilator,
* Position can be changed every 2 hours during the day and 4 hours at night,
* Patients whose relatives were approved to participate in the study.

Exclusion Criteria:

* Pneumonia develops prior to mechanical ventilation support or within the first 48 hours following mechanical ventilation support,
* Positive sputum culture was taken before mechanical ventilation support or within the first 48 hours following mechanical ventilation support,
* Patients with diabetes mellitus,
* Patients with contraindications for routine change of position
Investigating the Effectiveness of PelvicSense(R) on Pain and Sexual Outcomes in Provoked Vestibulodynia

This study will examine the effectiveness of the PelvicSense 3-month online program on pain and other outcomes in those with provoked vestibulodynia. This study is prospective in nature and will involve several assessment points: baseline, immediately post-treatment (at the end of the 3 month program), and 3-month follow up. All aspects of the study will be conducted remotely (e.g., online, email, video calls), and participants will be at least 18 years of age, fluent in English, and experience pain due to provoked vestibulodynia for at least 3 months with a physician diagnosis. Participants are expected to continue their treatment as usual and this information will be documented throughout the study.


Eligibility Criteria:
Inclusion Criteria:

* 18 years or older
* fluent in English
* have a formal diagnosis of PVD for at least 3 months

Exclusion Criteria:

* younger than 18 years of age
* nonfluent in English
* self-identified diagnosis
* PVD duration of less than 3 months
The Effect of Short Term Amiodarone Treatment After Catheter Ablation for Atrial Fibrillation

The purpose of this study is to examine the overall effectiveness of short-time anti-arrhythmic drug treatment with amiodarone (to control heart rhythm) to prevent short-and long-term atrial fibrillation following an ablation procedure for atrial fibrillation.

Atrial fibrillation (AF) is the most common cardiac arrhythmia, and it is associated with increased mortality and morbidity due to increased risk of stroke, poor quality of life and risk of developing heart failure.

Today, catheter ablation has become a standard procedure in the treatment of symptomatic atrial fibrillation, but so far there is no official recommendations regarding the use of antiarrythmic drugs after the procedure. Nevertheless, it is common standard practice to prescribe antiarrhythmic drugs for the first 2-3 months after the intervention to prevent early recurrences. To our knowledge, the effect of antiarrythmic drugs following ablation for atrial fibrillation has only been evaluated in a few recent studies. None of these have evaluated the long term effect of short term antiarrythmic drug treatment. In addition, none of the trials have been conducted placebo-controlled.

In this study patients with paroxysmal or persistent atrial fibrillation will be considered for randomisation. Following the ablation procedure, patients will be randomized to receive either amiodarone or placebo for a period of 8 weeks. Clinical visits including a physical exam, 12 lead ECG recording and blood samples, will be scheduled during the follow-up time. Furthermore patients will be evaluated with Quality of Life questionaires and Holter monitoring.

The primary endpoint of the study is freedom from atrial fibrillation, atrial flutter or atrial tachycardia at 6 months follow-up.

Eligibility Criteria:
Inclusion Criteria:

* Patients with symptomatic paroxysmal or persistent atrial fibrillation undergoing catheter ablation for atrial fibrillation. (persistent episodes may last no more than 12 months)

Exclusion Criteria:

* Contraindication or intolerance to amiodarone.
* Prolonged amiodarone treatment within 3 months before the planned ablation procedure.
* Previous participation in this study.
* Other cardiac arrythmias (patients with co-existing atrial flutter can be included).
* Antiarrhythmic treatment for indication other than atrial fibrillation (or atrial flutter).
* Heart failure (NYHA class III or IV or left ventricular ejection fraction \< 35%).
* Significant heart valve disease.
* Significant lung disease, thyroid dysfunction or liver disease.
* Inability or unwillingness to be treated with anticoagulation before and during the study.
* Females with birth giving potential
* Failure to give informed concent.
A New Cochlear Implant Electrode For Inner Ear Malformations

The custom made device was produced by Med-El Company. It has a "cork" like stopper instead of the usual silicon ring to prevent gusher. There are two types of electrodes consisting of different length. Standard one is 25 mm (contact space 1.7 mm) and the short one is 20 mm (contact space 1.3 mm). It was used in 50 patients with different inner ear malformations. Thirteen patients had gusher, and 11 patients oozing during cochleostomy. One patient with initial prototype of the cork electrode had to be revised because of persistent oozing around the electrode. Another patient had slow extrusion of the electrode most probably due to CSF (cerebrospinal fluid) pulsation and had to be revised. Both patients had no more CSF fistula.

CSF fistula in inner ear malformations is a serious situation which may lead to recurrent meningitis. The new cochlear implant electrode with "cork" stopper looks promising in preventing the postoperative CSF leak around the electrode.

Gusher in inner ear malformations is common in patients with incomplete partition type-I, and III. It is also common in less severe form as oozing in incomplete partition type II and large vestibular aqueduct. It is important to prevent CSF escape around the cochlear implant electrode to prevent meningitis.

The custom made device was produced by Med-El Company. It has a "cork" like stopper instead of the usual silicon ring to prevent gusher. There are two types of electrodes consisting of different length. Standard one is 25 mm (contact space 1.7 mm) and the short one is 20 mm (contact space 1.3 mm). It was used in 50 patients with different inner ear malformations.

Thirteen patients had gusher, and 11 patients oozing during cochleostomy. One patient with initial prototype of the cork electrode had to be revised because of persistent oozing around the electrode. Another patient had slow extrusion of the electrode most probably due to CSF pulsation and had to be revised. Both patients had no more CSF fistula.

CSF fistula in inner ear malformations is a serious situation which may lead to recurrent meningitis. The new cochlear implant electrode with "cork" stopper looks promising in preventing the postoperative CSF leak around the electrode.

Eligibility Criteria:
Inclusion Criteria:

* Must have an inner ear malformation
* Must meet the criteria for cochlear implantation

Exclusion Criteria:

* Prior cochlear implantation surgery
Volumetric Bone Mineral Density and it's Relationship With Osteoporotic Fractures in Parkinson's Disease

Idiopathic Parkinson's disease (IPD) is the second most frequent neurodegenerative disease. Its association with osteroporosis and fragility fracture is now clearly demonstrated, but the determinants of this osteoporosis are yet to be explained. Our aim was to study factors associated with volumetric bone mineral density (vBMD) and bone microstructure at the tibia and radius in IPD.


Eligibility Criteria:
Inclusion Criteria:

* Patients with idiopathic Parkinson's disease according to the criteria of the UKPDBB.
* Parkinson's disease of moderate severity (Index HOEHN and Yahr \<5)
* Patient can respond to questionnaires, with or without help

Exclusion Criteria:

* Patients with active psychiatric illness preventing the realization of examinations
* Severe Parkinson's disease (Index HOEHN and Yahr ≥5 )
* Heavy-morbidity including heart failure NYHA\> 3 or chronic respiratory failure, terminal or severe renal impairment known dialyzed
* Pregnancy
Clinical Trial of Autologous Adipose Tissue Derived Stromal Cell Therapy for Ischemic Heart Failure

Mesenchymal stem cells have capability to differentiate into myocardium, vascular endothelial cell, vascular smooth muscle cell and will be useful for heart regeneration. Adipose tissue is relatively enriched with mesenchymal stem cell compared to bone marrow tissue. In this trial, eligible ischemic heart failure patients will be proceeded intracoronary administration of autologous adipose tissue derived stromal cells by cardiac catheterization.

The population of the ischemic heart failure patients is enormous in Japan and the only radical treatment for them is heart transplantation: however, the number of giving donor is extremely limited. Mesenchymal stem cells have been capable to differentiate into mesodermal-lineage cells as well as endodermal-lineage cells such as myocardial cell. They reside in the mesenchymal tissues such as bone marrows as well as adipose tissues. The latter tissues are relatively enriched with mesenchymal stem cells compared to bone marrow cells. In this study, the ischemic heart failure patients will undergo intracoronary administration of autologous adipose tissue derived stromal cells through cardiac catheterization.

Eligibility Criteria:
Inclusion Criteria:

* Heart failure patients occured by prior ischemic event whose ejection fraction must be less than 40%.

Exclusion Criteria:

* Complicated severe other organ disease.
* Patient with malignancy.
* History of chemotherapy or irradiation within 4 weeks.
* Patient with immunodeficiency
* Pregnancy or possibility of pregnancy
* Candidate who are judged to be not applicable to this study by doctors.
Poor In Vitro Fertilisation Outcomes in Genital Tuberculosis - Case Report

This is a case series that highlights the challenges in instituting in vitro fertilisation (IVF) treatment amongs genital tuberculosis patients.

In this case series, the investigators recruited patients undergoing IVF treatment previously diagnosed with TB between 01/01/2014 and 30/06/2021. Patients were recruited at the beginning of their IVF treatments. Total sampling was employed for this study.

Eligibility Criteria:
Inclusion Criteria:

* patients with confirmed genital tuberculosis enrolling in in vitro fertilisation treatment

Exclusion Criteria:

* patients not confirmed to having genital tuberculosis